5:38 PM
 | 
Oct 01, 2009
 |  BC Extra  |  Clinical News

Chelsea gains after droxidopa data

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) jumped $0.51 (20%) to $3.02 on Thursday after reporting data from two Phase III trials of droxidopa to treat neurogenic orthostatic hypotension, including additional data...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >